Urgent

Acquired von Willebrand syndrome

Bleeding disorder · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A late-onset bleeding disorder from acquired loss of von Willebrand factor (VWF) — no personal/family history of a lifelong bleeding tendency. Mechanisms: autoantibodies and immune clearance (lymphoproliferative disease, MGUS/myeloma, SLE), adsorption onto malignant/abnormal cells (myeloproliferative neoplasms, Wilms tumour), increased shear-mediated proteolysis of high-molecular-weight (HMW) multimers (aortic stenosis — Heyde syndrome, HOCM, LVADs/ECMO), and hypothyroidism or drugs (valproate). Bleeding is typically mucocutaneous (epistaxis, bruising, GI — including angiodysplasia in Heyde) and post-procedural.

Red flags

  • New mucocutaneous or GI bleeding in an older adult with no prior bleeding history
  • Bleeding with a known paraprotein/MGUS, lymphoma, myeloproliferative neoplasm, aortic stenosis, LVAD/ECMO or hypothyroidism
  • Major or procedural bleeding with reduced VWF activity and loss of HMW multimers
  • GI bleeding from angiodysplasia (Heyde syndrome)

Assessment

Differential diagnosis

  • Inherited von Willebrand disease (lifelong history)
  • Immune thrombocytopenia / platelet function defect
  • Acquired haemophilia (factor VIII inhibitor)
  • Liver disease / DIC coagulopathy
  • Drug-induced bleeding (antiplatelets/anticoagulants)

Investigations

  • FBC/film, PT/APTT (APTT may be prolonged if FVIII low), fibrinogen
  • VWF antigen (VWF:Ag), VWF activity (VWF:GPIbM or ristocetin cofactor VWF:RCo) and factor VIII — activity often reduced out of proportion to antigen
  • VWF multimer analysis — loss of HIGH-MOLECULAR-WEIGHT multimers is characteristic
  • VWF propeptide-to-antigen ratio (raised — increased clearance); screen for the underlying cause: paraprotein/immunoglobulins, FBC for MPN, echocardiogram for aortic stenosis, TSH

Management

  • Resuscitate active bleeding (A–E, transfuse as needed) and STOP contributing antithrombotics.
  • Treat the UNDERLYING CAUSE — this is the definitive therapy: chemo/immunotherapy for lympho-/myelo-proliferative disease, valve replacement for aortic stenosis (corrects Heyde), thyroxine for hypothyroidism, remove the offending drug.
  • For acute bleeding or procedures, raise VWF/FVIII: options are VWF-containing concentrate or recombinant VWF, DDAVP (desmopressin — useful but short-lived, response variable), and TRANEXAMIC ACID as a mucosal-bleeding adjunct.
  • For antibody-mediated AVWS (e.g. MGUS-associated), INTRAVENOUS IMMUNOGLOBULIN (IVIG) often gives a durable response (especially IgG paraproteins); plasma exchange, corticosteroids, rituximab or immunosuppression are used in selected/refractory cases.
  • Monitor VWF activity/FVIII and clinical bleeding; because clearance is accelerated, replacement may need more frequent dosing than in inherited VWD.
  • Manage GI angiodysplasia bleeding (Heyde) supportively and definitively by correcting the aortic stenosis; involve haematology early.

Drugs & doses

Tranexamic acid (mucosal bleeding adjunct)
DDAVP / desmopressin (short-lived rise in VWF/FVIII; test response)
VWF concentrate or recombinant VWF (± factor VIII) for significant bleeding/procedures
IVIG (antibody/paraprotein-mediated AVWS); corticosteroids, rituximab, plasma exchange in selected cases
Disease-directed therapy for the underlying condition

Disposition

Admit active bleeding; urgent haematology involvement. Investigate and treat the underlying disorder (haem-onc, cardiology for aortic stenosis).

Complications & pitfalls

  • Major haemorrhage; refractory procedural bleeding
  • Recurrent GI bleeding (angiodysplasia)
  • Delayed diagnosis (mistaken for inherited VWD or other coagulopathy)
  • Bleeding complications of the underlying malignancy/therapy

Exam pearls

  • No lifelong bleeding history + new-onset mucocutaneous bleeding = think ACQUIRED VWS and hunt the cause.
  • Loss of high-molecular-weight multimers and a raised propeptide:antigen ratio point to acquired (clearance/proteolysis) rather than inherited disease.
  • Heyde syndrome = aortic stenosis + acquired VWS + GI angiodysplasia bleeding — valve replacement is curative.
  • Treat the cause: replacement and IVIG control bleeding, but the underlying disorder drives long-term management.

Suspect acquired von Willebrand syndrome in late-onset mucocutaneous/GI bleeding with no lifelong history — confirm with reduced VWF activity, low FVIII and loss of high-molecular-weight multimers, then hunt the underlying cause (paraprotein, MPN, aortic stenosis/Heyde, hypothyroidism, drugs, LVAD). Control bleeding with TXA, DDAVP, VWF concentrate/recombinant VWF and — for antibody-mediated disease — IVIG, while directing definitive therapy at the cause.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.